CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

The ELEGANCE registry, which is focused on historically underrepresented minorities and women, analyzed endovascular treatment ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

A post hoc analysis of the SIRONA trial investigated how sirolimus-coated balloon angioplasty compares to various paclitaxel dr ...

Data from the STRIDE study suggest that race, not sex, is associated with outcomes in acute limb ischemia (ALI) treated with me ...

The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the D ...

Two-year outcomes from the PROMISE II trial assessed transcatheter arterialization of the deep veins (TADV) using the LimFlow S ...

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with ...

Two-year outcomes were reported from the CLOUT registry, which is a prospective, multicenter study evaluating patient ...

The Disrupt PAD BTK II study’s 30-day outcomes were revealed. The core lab–adjudicated, prospective, multicenter, s ...